Nabota 200UI

Nabota 200UI, a type A botulinum toxin created by Daewoong Pharmaceutical Co., Ltd., has received approval from the U.S. Food and Drug Administration. This product marks the first Korean botulinum toxin to be introduced to the U.S. market, offering a cost-effective option that competes directly with Botox while maintaining the same handling protocols for this potentially toxic substance.

Description

Nabota 200UI, a botulinum toxin type A product from Daewoong Pharmaceutical Co., Ltd. in South Korea, combats facial wrinkles caused by uncontrolled muscle tone and active expressions. With over 30 years of biotechnological expertise, Nabota ensures rapid effectiveness and maintains a high standard of purity. Its benefits include:

• Quick Action: Rapid results in reducing facial wrinkles.
• High Standard of Cleanliness: Ensures a safe application process.
• Long-Lasting Effects: Provides extended relief from wrinkles.
• Natural Look: Does not “freeze” facial expressions, allowing for natural movement.
• High Security: Meets stringent safety standards for both practitioners and patients.

Application Areas:

• Facial Wrinkles: Effective for smoothing wrinkles around the eyebrows, eyes, mouth, nasolabial folds, and periorbital areas.
• Blepharospasm: Helps eliminate involuntary eyelid closure.
• Hyperhidrosis: Treats excessive sweating by targeting sweat glands.
• Botox Lifting: Utilized in non-surgical lifting procedures to enhance facial aesthetics.

Nabota is a trusted solution for both cosmetic enhancements and certain medical conditions, providing a safe and effective treatment option.